ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Roche Pact Targets Multiple Sclerosis

by Lisa M. Jarvis
June 30, 2014 | APPEARED IN VOLUME 92, ISSUE 26

Roche has teamed with venture capital firm Versant Ventures and the drug discovery incubator Inception Sciences to launch Inception 5, a biotech firm devoted to finding multiple sclerosis drugs. Inception 5 will use a screening platform developed at the University of California, San Francisco, to find small molecules that repair damaged myelin, the insulating layer around nerves. Versant will provide equity financing; Roche will provide milestone-based funding in exchange for the right to acquire Inception 5 down the road. This is the second build-to-buy company formed by the three partners. In 2012, they created Inception 3 to develop hearing loss treatments.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment